Read the Conversation
Conversation highlights:
- Direct Market Entry: Cipla, a 90+ year old global player, is establishing direct operations in Mexico after years of working through partnerships, targeting respiratory and oncology therapeutic areas.
- Strategic Market Timing: Mexico’s evolving regulatory environment and collaborative government mindset create the right conditions for direct investment and sustainable growth.
- Focused Portfolio Strategy: The company is concentrating on key areas where it can deliver meaningful impact, avoid oversaturated markets, and emphasize patient outcomes.
- Talent & Technology Investment: Success relies on building a skilled team aligned with Cipla’s “caring for life” philosophy and leveraging AI-driven information management to improve healthcare delivery.
- Medium-Term Growth Outlook: in 2026, and for the next 5 years, Cipla aims to expand into Mexico’s private market, scale products, develop partnerships, and enhance patient reach, positioning itself as a strategic long-term healthcare partner.
EF: What was your mission when appointed to establish Cipla in Mexico?
JR: Cipla’s Purpose has always been caring for life, and this philosophy defines our approach in every market, regardless of its size or demographic profile. I accepted this role because of the Mexican market’s strong fundamentals and clear potential for sustainable growth and development. As a company, we are not chasing quick wins; we are building a durable, credible presence and positioning ourselves as a serious, committed player. Over the next five years, our objective is to make a meaningful and lasting contribution to healthcare outcomes in Mexico.
EF: As a company with a 90-year legacy, what opportunity did you see, and why was this the right time to enter the Mexican market?
JR: Cipla operates in nearly seventy countries worldwide, through a combination of direct operations and strategic partnerships. Mexico is the second-largest pharmaceutical market in Latin America, and we've been operating through partnerships and distributors for years. However, the evolving landscape in both public and private sectors made direct presence more strategic. In parallel, we have also identified a more collaborative mindset from Mexican authorities compared to the past, which is critical for any multinational company entering a new market. This regulatory openness, combined with Mexico's market potential, created the right conditions for direct investment and operations.
EF: What types of partners are you currently seeking at this stage of your growth and collaboration efforts?
JR: Globally, we serve as a preferred partner for different companies, including multinationals we sometimes compete with in patent and non-patent categories. We view collaboration as a necessity rather than a choice to make medicines more accessible. Our approach focuses on expanding access to larger patient populations through strategic partnerships that leverage our respective strengths.
EF: Could you walk us through your current portfolio strategy in Mexico?
JR: As a newcomer establishing direct operations, we're taking a focused approach rather than spreading ourselves thin. We're concentrating on therapeutic areas where we have internal strength and see significant market opportunities: respiratory and oncology. These aren't cluttered markets where price alone determines success, but areas where we can contribute beyond just medications. This strategic focus allows us to make a meaningful impact rather than competing in oversaturated therapeutic classes.
EF: How has the market received Cipla’s products, and what key opportunities have you identified in respiratory and oncology?
JR: Wherever we've established a presence, Cipla products are accepted equally or even better than multinational or innovative companies because we deliver equal quality at much more accessible prices. Our goal is to ensure that every patient and every healthcare professional has access to the medicines they need.
EF: What type of team are you building for the future, and how are you attracting top talent in a highly competitive market like Mexico?
JR: We believe success depends on two critical pillars: products and people. Everything else supports those two foundations. We are confident in the quality of our products, so attracting the right people who truly embody the company’s spirit of caring for life and who are committed to the long term is essential. As a new organization in Mexico, we need to give our teams confidence by showing them how Cipla has built a strong reputation in other countries. We invest heavily in training to ensure our team members are partners, not just employees, and are supported with Cipla's values daily.
EF: How do you attract investment into Mexico, and why is one dollar invested in Mexico more compelling than investing elsewhere?
JR: Mexico offers a balanced opportunity for sustainable growth, especially because it has both a significant public sector and a growing private market. We also see political stability in the country, which is an important factor when making long-term investment decisions. The country has strong talent availability, and we see market opportunities where we can both contribute and grow.
From a portfolio perspective, Cipla has room to expand with new products in the coming years, including some that are not currently available in Mexico. We also expect the regulatory environment to continue evolving, potentially allowing faster approvals in the future. Delays in product approvals have been a challenge for the industry, so any improvement in that area would further support growth and innovation in the market.
EF: Looking ahead, where do you envision Cipla in Mexico, and what key decisions today will shape that future?
JR: We're planning to take significant steps into the private market, which we see as an opportunity to contribute. We're positive about market space availability and plan to scale up our efforts substantially. This means more products, more people, more partnerships, and ultimately serving more patients with Cipla medicines. The decisions we're making today around team building, regulatory positioning, and partnership development are all designed to support this expansion trajectory.
EF: Do you have any final message or remarks you would like to share?
JR: The therapeutic landscape is significantly evolving. When Cipla first started, the focus was mainly on acute conditions. Over time, however, patient needs have changed significantly. Today, there is a much stronger focus on chronic diseases, oncology, and increasingly on prevention and long-term care. As a company, we are especially proud of our leadership in respiratory care. We see strong potential in this area and want to strengthen our position further. Our ambition is that when people think about respiratory treatment, they naturally think of Cipla. That is the kind of recognition we aim to build, including in markets like Mexico.
